

Roy M Gulick

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3080785/publications.pdf>

Version: 2024-02-01

113
papers

14,040
citations

71102

41
h-index

30087

103
g-index

113
all docs

113
docs citations

113
times ranked

17778
citing authors

#	ARTICLE	IF	CITATIONS
1	Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 7367-7380.	3.5	13
2	Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and women: HPTN 069/ACTG A5305. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 500-506.	3.0	2
3	Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitorâ€“Containing Regimens. <i>Clinical Infectious Diseases</i> , 2021, 73, e2153-e2163.	5.8	32
4	Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel. <i>Annals of Internal Medicine</i> , 2021, 174, 93-95.	3.9	38
5	Blood component utilization in COVIDâ€“19 patients in New York City: Transfusions do not follow the curve. <i>Transfusion</i> , 2021, 61, 692-698.	1.6	18
6	The Uncertain Role of Corticosteroids in the Treatment of COVID-19. <i>JAMA Internal Medicine</i> , 2021, 181, 140.	5.1	4
7	Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab014.	0.7	4
8	Randomized Pilot Study of an Advanced Smart-Pill Bottle as an Adherence Intervention in Patients With HIV on Antiretroviral Treatment. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 73-80.	2.1	6
9	Tissue specificity-aware TWAS (TSA-TWAS) framework identifies novel associations with metabolic, immunologic, and virologic traits in HIV-positive adults. <i>PLoS Genetics</i> , 2021, 17, e1009464.	3.5	11
10	Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxis. <i>Aids</i> , 2021, 35, 1585-1595.	2.2	10
11	Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteria. <i>Aids</i> , 2021, 35, 2225-2227.	2.2	11
12	Developing Treatment Guidelines During a Pandemic Health Crisis: Lessons Learned From COVID-19. <i>Annals of Internal Medicine</i> , 2021, 174, 1151-1158.	3.9	16
13	Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. <i>New England Journal of Medicine</i> , 2021, 385, 595-608.	27.0	359
14	Selecting Treatments During an Infectious Disease Pandemic: Chasing the Evidence. <i>Annals of Internal Medicine</i> , 2021, 174, 1464-1465.	3.9	4
15	HIV: Closing the Mortality Gap. <i>Annals of Internal Medicine</i> , 2021, 174, 1311-1312.	3.9	1
16	Managing HIV Treatment Failure: Time to REVAMP?. <i>Annals of Internal Medicine</i> , 2021, , .	3.9	0
17	Drug Costs: What Can Infectious Diseases Physicians Do?. <i>Journal of Infectious Diseases</i> , 2020, 221, 681-684.	4.0	1
18	Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 254-255.	1.1	2

#	ARTICLE	IF	CITATIONS
19	HIV treatment and prevention 2019. Current Opinion in HIV and AIDS, 2020, 15, 4-12.	3.8	52
20	Obesity and COVID-19 in New York City: A Retrospective Cohort Study. Annals of Internal Medicine, 2020, 173, 855-858.	3.9	72
21	Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease. PLoS ONE, 2020, 15, e0236778.	2.5	21
22	COVID-19 in Hospitalized Adults With HIV. Open Forum Infectious Diseases, 2020, 7, ofaa327.	0.9	42
23	Severe Covid-19. New England Journal of Medicine, 2020, 383, 2451-2460.	27.0	1,147
24	Clinical Characteristics of Covid-19 in New York City. New England Journal of Medicine, 2020, 382, 2372-2374.	27.0	1,836
25	Prioritizing clinical research studies during the COVID-19 pandemic: lessons from New York City. Journal of Clinical Investigation, 2020, 130, 4522-4524.	8.2	10
26	Title is missing!. , 2020, 15, e0236778.		0
27	Title is missing!. , 2020, 15, e0236778.		0
28	Title is missing!. , 2020, 15, e0236778.		0
29	Title is missing!. , 2020, 15, e0236778.		0
30	Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 copies/mL: week 48 outcomes from ACTG 5353. Journal of Antimicrobial Chemotherapy, 2019, 74, 1376-1380.	3.0	19
31	Comparable viral decay with initial dolutegravir plus lamivudine versus dolutegravir-based triple therapy. Journal of Antimicrobial Chemotherapy, 2019, 74, 2365-2369.	3.0	11
32	Perspectives of US women participating in a candidate PrEP study: adherence, acceptability and future use intentions. Journal of the International AIDS Society, 2019, 22, e25247.	3.0	15
33	Racial Disparities in Virologic Failure and Tolerability During Firstline HIV Antiretroviral Therapy. Open Forum Infectious Diseases, 2019, 6, ofz022.	0.9	4
34	ART in HIV-Positive Persons With Low Pretreatment Viremia: Results From the START Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 456-462.	2.1	8
35	The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM. Aids, 2019, 33, 237-246.	2.2	17
36	Long-Acting HIV Drugs for Treatment and Prevention. Annual Review of Medicine, 2019, 70, 137-150.	12.2	87

#	ARTICLE	IF	CITATIONS
37	Genetic Variation of the Kinases That Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear Cells. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 421-429.	1.1	13
38	ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)â€“infected Participants With HIV-1 RNA <500000 Copies/mL. <i>Clinical Infectious Diseases</i> , 2018, 66, 1689-1697.	5.8	83
39	Editorial. <i>Current Opinion in HIV and AIDS</i> , 2018, 13, 291-293.	3.8	8
40	No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305. <i>PLoS ONE</i> , 2018, 13, e0206577.	2.5	3
41	Combination therapy with anti-HIV-1 antibodies maintains viral suppression. <i>Nature</i> , 2018, 561, 479-484.	27.8	392
42	Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. <i>Nature Medicine</i> , 2018, 24, 1701-1707.	30.7	195
43	Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. <i>Pharmacogenetics and Genomics</i> , 2018, 28, 179-187.	1.5	4
44	Relationship between latent and rebound viruses in a clinical trial of antiâ€“HIV-1 antibody 3BNC117. <i>Journal of Experimental Medicine</i> , 2018, 215, 2311-2324.	8.5	84
45	The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. <i>Journal of Infectious Diseases</i> , 2018, 218, 1954-1963.	4.0	130
46	Investigational Antiretroviral Drugs: What is Coming Down the Pipeline. <i>Topics in Antiviral Medicine</i> , 2018, 25, 127-132.	0.1	22
47	PHASE 2 STUDY OF THE SAFETY AND TOLERABILITY OF MARAVIROC-CONTAINING REGIMENS TO PREVENT HIV INFECTION IN MEN WHO HAVE SEX WITH MEN (MSM) (HPTN 069/ACTG A5305). <i>Journal of Infectious Diseases</i> , 2017, 215, jiw525.	4.0	40
48	Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. <i>Nature Medicine</i> , 2017, 23, 185-191.	30.7	399
49	Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women. <i>Annals of Internal Medicine</i> , 2017, 167, 384.	3.9	29
50	Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants. <i>Journal of Infectious Diseases</i> , 2017, 216, 554-564.	4.0	23
51	A Conversation Among the IAS-USA Board of Directors: Hot Topics and Emerging Data in HIV Research and Care. <i>Topics in Antiviral Medicine</i> , 2017, 24, 142-151.	0.1	0
52	Invasive <i>Aspergillus</i> Sinusitis in Human Immunodeficiency Virus Infection: Case Report and Review of the Literature. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw135.	0.9	11
53	HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. <i>Nature</i> , 2016, 535, 556-560.	27.8	400
54	The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States. <i>Clinical Infectious Diseases</i> , 2016, 62, 784-791.	5.8	50

#	ARTICLE	IF	CITATIONS
55	Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofu113.	0.9	37
56	Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. <i>Nature</i> , 2015, 522, 487-491.	27.8	665
57	HIV treatment 2020: what will it look like?. <i>Journal of the International AIDS Society</i> , 2014, 17, 19528.	3.0	10
58	1721Cost-Effectiveness of Meningococcal Quadrivalent Conjugate Vaccination Campaign among Men Who Have Sex With Men in New York City. <i>Open Forum Infectious Diseases</i> , 2014, 1, S461-S462.	0.9	0
59	1615Pregnancy-Related Outcomes and Mortality in the Years Following Pregnancy among Women Perinatally Infected with HIV “ New York City, 2005“2011. <i>Open Forum Infectious Diseases</i> , 2014, 1, S431-S431.	0.9	0
60	Five-Year Safety Evaluation of Maraviroc in HIV-1“Infected Treatment-Experienced Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 78-81.	2.1	36
61	Association Between Efavirenz as Initial Therapy for HIV-1 Infection and Increased Risk for Suicidal Ideation or Attempted or Completed Suicide. <i>Annals of Internal Medicine</i> , 2014, 161, 1.	3.9	175
62	Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu018.	0.9	7
63	Antiretroviral Therapy and Efficacy After Virologic Failure on First-line Boosted Protease Inhibitor Regimens. <i>Clinical Infectious Diseases</i> , 2014, 59, 888-896.	5.8	15
64	Invasive Meningococcal Disease in Men Who Have Sex With Men. <i>Annals of Internal Medicine</i> , 2013, 159, 300.	3.9	36
65	Racial Differences in Response to Antiretroviral Therapy for HIV Infection: An AIDS Clinical Trials Group (ACTG) Study Analysis. <i>Clinical Infectious Diseases</i> , 2013, 57, 1607-1617.	5.8	40
66	Next-generation oral preexposure prophylaxis. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 600-606.	3.8	29
67	Cost-effectiveness of Adding an Agent That Improves Immune Responses to Initial Antiretroviral Therapy (ART) in HIV-Infected Patients: Guidance for Drug Development. <i>HIV Clinical Trials</i> , 2012, 13, 1-10.	2.0	8
68	CCR5 Antagonism in HIV Infection: Current Concepts and Future Opportunities. <i>Annual Review of Medicine</i> , 2012, 63, 81-93.	12.2	60
69	Virologic, clinical and immunologic responses following failure of first-line antiretroviral therapy in Haiti. <i>Journal of the International AIDS Society</i> , 2012, 15, 17375.	3.0	23
70	Change in High-Sensitivity C-Reactive Protein Levels Following Initiation of Efavirenz-Based Antiretroviral Regimens in HIV-Infected Individuals. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 461-468.	1.1	30
71	Reanalysis of Coreceptor Tropism in HIV-1-Infected Adults Using a Phenotypic Assay with Enhanced Sensitivity. <i>Clinical Infectious Diseases</i> , 2011, 52, 925-928.	5.8	42
72	Episomal Viral cDNAs Identify a Reservoir That Fuels Viral Rebound after Treatment Interruption and That Contributes to Treatment Failure. <i>PLoS Pathogens</i> , 2011, 7, e1001303.	4.7	70

#	ARTICLE	IF	CITATIONS
73	The Relationship of CCR5 Antagonists to CD4+ T-Cell Gain: A Meta-Regression of Recent Clinical Trials in Treatment-Experienced HIV-Infected Patients. <i>HIV Clinical Trials</i> , 2010, 11, 351-358.	2.0	27
74	Antiretroviral Treatment 2010: Progress and Controversies. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 55, S43-S48.	2.1	23
75	Substitution of Nevirapine because of Efavirenz Toxicity in AIDS Clinical Trials Group A5095. <i>Clinical Infectious Diseases</i> , 2010, 50, 787-791.	5.8	29
76	Early versus Standard Antiretroviral Therapy for HIV-Infected Adults in Haiti. <i>New England Journal of Medicine</i> , 2010, 363, 257-265.	27.0	329
77	Long-Term Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals (ACTG 5097s). <i>HIV Clinical Trials</i> , 2009, 10, 343-355.	2.0	100
78	Raltegravir: The First HIV Type 1 Integrase Inhibitor. <i>Clinical Infectious Diseases</i> , 2009, 48, 931-939.	5.8	135
79	Quantitative Deep Sequencing Reveals Dynamic HIV-1 Escape and Large Population Shifts during CCR5 Antagonist Therapy In Vivo. <i>PLoS ONE</i> , 2009, 4, e5683.	2.5	205
80	Maraviroc for Previously Treated Patients with R5 HIV-1 Infection. <i>New England Journal of Medicine</i> , 2008, 359, 1429-1441.	27.0	708
81	HIV/AIDS: When to Start Antiretroviral Therapy?. <i>Clinical Infectious Diseases</i> , 2008, 47, 1580-1586.	5.8	26
82	In Vivo Emergence of Vicriviroc Resistance in a Human Immunodeficiency Virus Type 1 Subtype C-Infected Subject. <i>Journal of Virology</i> , 2008, 82, 8210-8214.	3.4	110
83	Survival, plasma HIV-1 RNA concentrations and drug resistance in HIV-1-infected Haitian adolescents and young adults on antiretrovirals. <i>Bulletin of the World Health Organization</i> , 2008, 86, 970-977.	3.3	35
84	Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5 Inhibitor, in HIV-1-Infected, Treatment-Experienced Patients: AIDS Clinical Trials Group 5211. <i>Journal of Infectious Diseases</i> , 2007, 196, 304-312.	4.0	237
85	HIV Type 1 Chemokine Coreceptor Use among Antiretroviral-Experienced Patients Screened for a Clinical Trial of a CCR5 Inhibitor: AIDS Clinical Trial Group A5211. <i>Clinical Infectious Diseases</i> , 2007, 44, 591-595.	5.8	179
86	Evidence of Ongoing Immune Reconstitution in Subjects with Sustained Viral Suppression following 6 Years of Lopinavir-Ritonavir Treatment. <i>Clinical Infectious Diseases</i> , 2007, 44, 749-754.	5.8	38
87	Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression. <i>Aids</i> , 2007, 21, 813-823.	2.2	22
88	Antiretroviral Management of Treatment-Naive Patients. <i>Infectious Disease Clinics of North America</i> , 2007, 21, 71-84.	5.1	2
89	Three- vs Four-Drug Antiretroviral Regimens for the Initial Treatment of HIV-1 Infection₁²; A Randomized Controlled Trial₁². <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 769.	7.4	209
90	Pharmacogenetics of Plasma Efavirenz Exposure after Treatment Discontinuation: An Adult AIDS Clinical Trials Group Study. <i>Clinical Infectious Diseases</i> , 2006, 42, 401-407.	5.8	208

#	ARTICLE	IF	CITATIONS
91	Editorial Commentary:Adherence to Antiretroviral Therapy: How Much Is Enough?. Clinical Infectious Diseases, 2006, 43, 942-944.	5.8	38
92	Design Issues in Initial HIV-Treatment Trials: Focus on Actg A5095. Antiviral Therapy, 2006, 11, 751-760.	1.0	13
93	Antiretroviral Therapy in a Thousand Patients with AIDS in Haiti. New England Journal of Medicine, 2005, 353, 2325-2334.	27.0	249
94	Antiretroviral therapies for treatment-experienced patients: current status and research challenges. Aids, 2005, 19, 747-756.	2.2	42
95	Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals. Annals of Internal Medicine, 2005, 143, 714.	3.9	226
96	Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients. Aids, 2004, 18, 775-779.	2.2	98
97	Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection. New England Journal of Medicine, 2004, 350, 1850-1861.	27.0	495
98	Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. Aids, 2004, 18, 2391-400.	2.2	429
99	Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. Aids, 2003, 17, 2345-2349.	2.2	52
100	Dual vs Single Protease Inhibitor Therapy Following Antiretroviral Treatment Failure<SUBTITLE>A Randomized Trial</SUBTITLE>. JAMA - Journal of the American Medical Association, 2002, 288, 169.	7.4	160
101	Durability of Response to Treatment among Antiretroviralâ€œExperienced Subjects: 48â€œWeek Results from AIDS Clinical Trials Group Protocol 359. Journal of Infectious Diseases, 2002, 186, 626-633.	4.0	12
102	New drugs for HIV therapy. Aids, 2002, 16, S135-S144.	2.2	6
103	Structured Treatment Interruption in Patients Infected with HIV. Drugs, 2002, 62, 245-253.	10.9	31
104	Analysis of Virological Efficacy in Trials of Antiretroviral Regimens: Drawbacks of Not Including Viral Load Measurements after Premature Discontinuation of Therapy. Antiviral Therapy, 2002, 7, 271-281.	1.0	14
105	ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. Aids, 2001, 15, F1-F9.	2.2	206
106	A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I). Aids, 2000, 14, 1591-1600.	2.2	76
107	Competing drugâ€œdrug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884. Aids, 2000, 14, 2495-2501.	2.2	45
108	Phase I Studies of Hypericin, the Active Compound in St. John's Wort, as an Antiretroviral Agent in HIV-Infected Adults: AIDS Clinical Trials Group Protocols 150 and 258. Annals of Internal Medicine, 1999, 130, 510.	3.9	85

#	ARTICLE	IF	CITATIONS
109	HIV Treatment Strategies. JAMA - Journal of the American Medical Association, 1998, 279, 957.	7.4	20
110	Simultaneous vs Sequential Initiation of Therapy With Indinavir, Zidovudine, and Lamivudine for HIV-1 Infection. JAMA - Journal of the American Medical Association, 1998, 280, 35.	7.4	228
111	Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy. New England Journal of Medicine, 1997, 337, 734-739.	27.0	1,823
112	Current antiretroviral therapy: an overview. Quality of Life Research, 1997, 6, 471-474.	3.1	27
113	Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305). AIDS and Behavior, 0, , .	2.7	1